Jonathan Winger

Jonathan Winger is co-inventor of the H-NOX technology from which OMX therapeutics are derived, and has 20+ years of experience with production and study of H-NOX and other proteins. Prior to assuming the role of CEO, he oversaw the design and characterization of candidate OMX therapeutics, directed process and analytical development, and managed the manufacture of clinical material. Prior to Omniox, Jonathan was an American Heart Association Postdoctoral Fellow at the University of California, Berkeley, where he carried out biochemistry and structural biology studies on H-NOX proteins, kinases, and other proteins. He obtained his PhD in Medicinal Chemistry at the University of Michigan, where he used spectroscopy and enzymology to study the role of soluble guanylate cyclase (sGC), an H-NOX-containing protein, in nitric oxide signaling pathways. Insights gained from this work contributed to the conception and founding of Omniox. Jonathan has published numerous research papers and abstracts, co-authored several book chapters, is a PI on several research grants, and is an inventor on multiple patents.